CHINESE JOURNAL OF DRUG EVALUATION >

2026 , Vol. 43 >Issue 2: 143 - 143-150

DOI: https://doi.org/10.2095-3593.2026.040010

Cost-Benefit Analysis of Closed-System and Open-System Infusion of Human Serum Albumin in ICU Patients

Expand
  • 1.Health Economic Research Institute，School of Pharmaceutical Sciences， Sun Yat-Sen University， Guangdong Guangzhou 510006， China；
    2.Department of Pharmacy，The First Affiliated Hospital of Sun Yatsen University， Guangdong Guangzhou 510080， China；
    3.Aerospace Center Hospital， Beijing 100049， China；
    4.Department of PharmacyShanxi Provincial People′s Hospital， Shaanxi Xi′an 710068， China；
    5.Pharmacy Center，Shandong Public Health Clinical Center， Shandong Jinan 250013， China；
    6.Medical Affairs Takeda (China) International Trading Company， Beijing 100027， China；
    7.Ruijin Hospital School of Medicine， Shanghai Jiaotong University， Shanghai 200025， China

Received date: 2025-11-11

  Revised date: 2026-02-24

  Accepted date: 2026-05-19

  Online published: 2026-05-19

Fold

Abstract

Objective： To evaluate the cost-benefit profiles between closed-system albumin infusion (bagged) and open-system albumin infusion (bottled) in the intensive care unit (ICU) in China， so as to provide multi-perspective evidence for clinical medication decisions and health resource allocation. Methods： A one-year decision tree model was constructed to simulate the clinical pathways and economic burden of 100 ICU patients receiving closed-system versus open-system albumin infusion. The model used central line-associated bloodstream infection (CLABSI) incidence rate as the primary node， and comprehensively incorporated drug costs， preparation costs， storage and management costs， hospitalization expenses， and caregiver costs. Cost-benefit analysis was conducted from the perspectives of healthcare institutions， patients， and payers. Results： In terms of cost， although closed-system albumin had a higher unit drug cost， it resulted in lower total hospitalization costs， and yielded savings in drug preparation costs and storage and management costs. From different perspectives， the use of closed-system albumin was associated with average cost savings of 205 RMB per case (healthcare institution perspective)， 51 RMB (patient perspective) and 95 RMB (payer’s perspective). Regarding clinical outcomes， compared to open-system albumin， closed-system albumin could reduce mortality， CLABSI incidence rate， ICU bed occupancy rate， ICU infection-related complications rate， and ICU secondary endocarditis incidence rate. Additionally， closed-system albumin shortened ICU length of stay. Closed-system albumin saved 218 minutes of drug preparation time for 100 simulated patients， reducing medication waste. Both one-way sensitivity analysis and probabilistic sensitivity analysis demonstrated the robustness of the model results. Conclusion： The use of closed-system albumin in ICU patients is more cost-beneficial than open-system albumin， reducing medical costs， improving clinical outcomes， and bringing comprehensive benefits to healthcare institutions， patients， and the health insurance system.

Key words： ; font-size:medium; ">Albumin； Closed-system infusion； Cost-benefit analysis； Intensive care unit

Cite this article

JIAN Yifei, TANG Kejing, XUE Xiaoyan, ZHANG Peng, WANG Congrong, GAO Yongbo, BIAN Xiaolan, XUAN Jianwei . Cost-Benefit Analysis of Closed-System and Open-System Infusion of Human Serum Albumin in ICU Patients[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026 , 43(2) : 143 -143-150 . DOI: 10.2095-3593.2026.040010

References

  [1] Callum J， Skubas NJ， Bathla A， et al. Use of intravenous albumin： a guideline from the international collaboration for transfusion medicine guidelines[J]. Chest， 2024，166(2)：321-338.
     [2] 中国药学会医院药学专业委员会. 人血白蛋白临床应用管理中国专家共识[J]. 中国医院药学杂志， 2024，44(7)：739-751.
     [3] 曾晶， 徐萍， 王清， 等. 8760例住院患者人血白蛋白临床使用分析与评价[J]. 中国药房， 2017，28(8)：1027-1030.
     [4] Maki G， Rosenthal VD， Salomao R， et al. Impact of switching from an open to a closed infusion system on rates of central line-associated bloodstream infection： a meta-analysis of time-sequence cohort studies in 4 countries[J]. Infect Control Hosp Epidemiol， 2011，32(1)：50-58.
     [5] Nickel B， Gorski L， Kleidon T， et al. Infusion therapy standards of practice， 9th edition[J]. J Infus Nurs， 2024，47(1S Suppl 1)：S1-S285.
     [6] 冯燕， 吴丹. 白蛋白袋式装置在重症医学科临床中的实用性效果观察[J]. 华西医学， 2014，29(10)：1966-1967.
     [7] Tarricone R， Torbica A， Franzetti F， et al. Hospital costs of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of intensive care units in Italy[J]. Cost Eff Resour Alloc， 2010，8：8.
     [8] 刘雪丽， 郑丽英， 胡欣， 等. 基于医院获得性感染风险的封闭式输注人血白蛋白经济性评价[J]. 药物不良反应杂志， 2019，6(21)：425-430.
     [9] Pedrolo E， Danski M， Wiens A， et al. Cost effectiveness of dressing in the prevention of catheter-related infection in critically ill patients[J]. J Infect Dev Ctries， 2018，12(10)：871-877.
     [10] Guidet B， Ghout I， Ropers J， et al. Economic model of albumin infusion in septic shock： the EMAISS study[J]. Acta Anaesthesiol Scand， 2020，64(6)：781-788.
     [11] 药智网. 人血白蛋白中标价[EB/OL]. (2025-07-08) [2025-07-23]. https：//vip. yaozh. com/search?comprehensive=drug&searchwords=%E7%99%BD%E8%9B%8B%E7%99%BD&source=1.
     [12] 蔡莉， 冯晓敏， 黄竞， 等. ICU重症患者中心静脉导管相关血流感染的卫生经济学分析[J]. 中山大学学报(医学科学版)， 2025，46(2)：301-310.
     [13] Chovanec K， Arsene C， Gomez C， et al. Association of CLABSI with hospital length of stay， readmission rates， and mortality： a retrospective review[J]. Worldviews Evid Based Nurs， 2021，18(6)：332-338.
     [14] Zeng C， Wu A， Li L， et al. Multi-center prospective study on central line-associated bloodstream infections in 79 ICUs of China[J]. BMC Infect Dis， 2021，21(1)：1208.
     [15] Zhong Y， Zhou L， Liu X， et al. Incidence， risk factors， and attributable mortality of catheter-related bloodstream infections in the intensive care unit after suspected catheters infection： a retrospective 10-year cohort study[J]. Infect Dis Ther， 2021，10(2)：985-999.
     [16] Miller LM， Clark E， Dipchand C， et al. Hemodialysis tunneled catheter-related infections[J]. Can J Kidney Health Dis， 2016，3：1-11.
     [17] Lok CE， Mokrzycki MH. Prevention and management of catheter-related infection in hemodialysis patients[J]. Kidney Int， 2011，79(6)：587-598.
     [18] 蔡源益. 中心静脉导管相关血流感染现状和住院费用负担研究[D]. 沈阳：中国医科大学， 2018.
     [19] Flexbumin产品官网[EB/OL]. (2024-01-30) [2025-07-23]. https：//www. flexbumin. com/.
     [20] 国家统计局. 医疗保健类居民消费价格指数(上年=100) [EB/OL]. (2024-12-30) [2025-07-23]. https：//data. stats. gov. cn/.
     [21] 国家卫生健康委员会规划发展与信息化司. 2023年我国卫生健康事业发展统计公报[EB/OL]. (2024-08-29) [2025-07-23]. https：//www. gov. cn/lianbo/bumen/202408/content_6971241. htm.
     [22] 武迎宏， 曹煜隆， 周春莲， 等. 中央导管相关血流感染经济损失的病例对照研究[J]. 中华医院感染学杂志， 2018，28(17)：2615-2617.
     [23] 国家卫生健康委员会. 重症医学专业医疗质量控制指标（2024年版）[EB/OL]. （2024-12-27）[2025-07-23]. https：//www. gov. cn/zhengce/zhengceku/202409/content_6975963. htm.
     [24] Li L， Yang W， Tang X， et al. The impacts of the diagnosis-related group payment reform on hospitalization-related medical expenses： evidence from China[J]. Health Econ Rev， 2025，15(1)：94.
     [25] Rosenthal VD， Memish ZA， Shweta F， et al. Preventing central line-associated bloodstream infections： a position paper of the international society for infectious diseases， 2024 update[J]. Int J Infect D， 2025，150：107290.
     [26] 陈宇堃， 陈倩茹， 邓锋， 等. 人血白蛋白中铝离子含量稳定性试验结果的探讨[J]. 中国药品标准， 2019，20(4)：332-338.
     [27] Carbon Footprint & Product Labelling Scheme： Carbon Footprint Certification Letter(2008) [M]. Version 1.0. London： Carbon Trust， 2008.
Options
Outlines

/

〈 〉

[an error occurred while processing this directive]